Scinovex
Health Sciences → Medicine → Hematology

Chronic Myeloid Leukemia Treatments

This cluster of papers focuses on the efficacy and resistance of various tyrosine kinase inhibitors, such as Imatinib, Dasatinib, and Nilotinib, in the treatment of Chronic Myeloid Leukemia (CML). The papers discuss molecular mechanisms of resistance, mutation analysis, leukemia stem cells, treatment discontinuation, and long-term outcomes of different targeted therapies.

67.2K works worldwide954.4K citations
ImatinibBCR-ABLTyrosine Kinase InhibitorsResistanceMutationLeukemia Stem CellsMolecular ResponseTreatment DiscontinuationDasatinibNilotinib

Journals publishing in this area

Articles on Scinovex in this research area

2 articles, most cited first

  1. Mathematical modelling of acute myeloid Leukaemia with dynamics of accidental cell death
    International Journal of Statistics and Applied Mathematics · 2023 · 2 citations
  2. Unveiling the protective potential: Naringenin's role in mitigating methotrexate induced hematological alterations
    International Journal of Advanced Biochemistry Research · 2025 · 0 citations